Softox Solutions As · OSL:SOFTX
Softox Solutions As — Investor Presentation (December 2019)
28 slides from Softox Solutions As's investor presentation, December 2019
Slide 1: Preventing and treating chronic infections
Preventing and treating chronic infections SoftOx Solutions AS A Norwegian MedTech Company listed on Merkur, OSE
Slide 2: Disclaimer
Disclaimer This Presentation has been produced by SoftOx Solutions AS (the “Company” or “SoftOx”), solely for use at the presentation to investors held in connection with the proposed private placement of shares by the Company. This presentation is strictly confidential and may not be reproduced or
Slide 3: Risk factors
Risk factors Investments in shares always entail a high degree of risk. Potential investors should give careful consideration to the specific factors listed below, which is a non-exhaustive list of certain risks and uncertainties inherent in any investment in securities issued by SoftOx. Each of the
Slide 4: Risk factors cont.
Risk factors cont. • SoftOx may face competition from new as well as from known competing products. If the Company is unable to compete effectively, in terms of its products or prices, it may have to alter the design of its clinical programmes, its overall costs may increase and the Company may be u
Slide 5: Highlights
Highlights SoftOx has discovered a unique combination of natural chemicals proven to have superior antimicrobial effect compared to today’s solutions* • First clinical trial in humans completed successfully • Secured distribution agreements for hand disinfection (Kiiltoclean/Antibac) and animal heal
Slide 6: Company background
Company background 1 • Extensive experience from animal husbandry in the European agricultural sphere • Key observations: Background » 20% of cows suffer from chronic bacterial infections1 » Antibiotic treatments are mostly ineffective in biofilm infections and cause bacterial resistance » Hypochlor
Slide 7: Key personnel
Key personnel Geir H. Almås, CPA – Chief Executive Officer & Founder Hans Jørgen Holum - CEO SoftOx Denmark & Head of Animal Health • Extensive experience from business development • Over 20 years’ experience with international sales and management positions • Previously PwC and KLP Asset Management
Slide 8: Key partners and contributors
Key partners and contributors Strong international support from key opinion leaders and institutions 8
Slide 9: The challenge
The challenge Antimicrobial resistance The ability of bacteria and other microorganisms to resist the effects of an antibiotic/antiseptic to which they were once sensitive Biofilm resistance Aggregated bacteria often covered by slime (biofilm matrix), acting as a fortress and protect bacteria from a
Slide 10: A unique combination
A unique combination Hypochlorous acid Acetic acid • The body’s natural antimicrobial agent • Long history of use as an antiseptic • Widely used but inherently unstable • Potentially effective deep within the wound bed • Instantaneous microbial killing effect • Good stability • Superior safety profi
Slide 11: SoftOx works both on wound surface and beneath wound bed
SoftOx works both on wound surface and beneath wound bed The SoftOx Wound Model Success criteria for removal of infections ▪ Penetrate and kill microbes within the biofilm Prevent infections ▪ Penetrate and eradicate biofilm also within the wound bed ▪ Not cause development of microbial resistance t
Slide 12: Pre-clinical experiments show promising effects
Pre-clinical experiments show promising effects In vitro in the lab Animal models ✓ A safe disinfectant with a unique ability to remove hard-to- ✓ No negative influence on wound healing treat microbes embedded in biofilm ✓ Appears to be significantly more effective than competitors ✓ Well-tolerated
Slide 13: Multiple areas of use – current focus on hands and wounds
Multiple areas of use – current focus on hands and wounds Humans Animals Chronic otitis media, chronic Chronic and acute wounds; Mastitis sinusitis, chronic tonsillitis, dental leg wounds in particular plaque, pre and post operative Peripheral vascular catheters, stomi, urinary catheters and urinary
Slide 14: Conducted preclinical and clinical studies
Conducted preclinical and clinical studies Cost Study Objectives Results Completed (NOK) Costerton Biofilm Center: Multiple experiments Superior antimicrobial effect documented for a range of concentrations on surface biofilms to define optimal (HOAc: 0.25%-4%, HOCl: 100-1000ppm). Tests showed signi
Slide 15: Human pilot study on safety in patients with acute wounds
Human pilot study on safety in 12 patients with acute wounds Primary Objective The primary objective of this clinical investigation is to document safety of the SoftOx Wound Irrigation Solution when used on split skin graft donor sites1 in an adult population Secondary Objectives The secondary objec
Slide 16: Clinical studies in progress/to be conducted
Clinical studies in progress/to be conducted Cost Expected to Study Objectives (NOK) be ready Animal (minipigs); MAX RTC: Local tolerance, systemic effects and pathology in minipigs after repeated dosing (continuously for 28 days) with 4m Q2-3 2020 dose; wound healing increasing SOX-strengths. Aimin
Slide 17: Product development plan
Product development plan 1 Preclinical/EN Application market Market introduction Voluntary post Hand Disinfection In vitro/EN studies studies approval Nordic region market studies SafeDes 1H2020 2020 2 Preclinical/EN Voluntary post Animals In vitro/EN studies Pilot/PoC Market introduction studies ma
Slide 18: Product portfolio
Product portfolio Biocide expected to be Medical Device SoftOx platform ready for Expected ready for Medical Drug developed market in 2020 market in 2021 1 Hand disinfectant Ready for Nordic market 3 Wound Irrigation Solution SoftOx • Acute wounds Technology (Surgical/Burns/Cuts) base • Chronic woun
Slide 19: Go-to-market strategy: Hand disinfection
Go-to-market strategy: 1 Hand disinfection Sales channels and target market Healthcare savings and revenue scenario USDm ▪ Sales through distribution partners 600 ▪ Nordics/Baltics: Kiiltoclean (Antibac), market leader in the 576 region (est. >50% market share) 550 ▪ Rest of Europe: In progress 500
Slide 20: Go-to-market strategy: Animal wound- and disinfection market
Go-to-market strategy: 2 Animal wound- and disinfection market Sales channels and market entry Animal care revenue scenario – gross market USDm ▪ First distribution agreement with VESO, a strong distributor to 44 43 the Norwegian veterinary healthcare market 42 40 ▪ Planned launch of first products
Slide 21: Go-to-market strategy: Medical device (SWIS) Infection remover (drug)
Go-to-market strategy: 3 Medical device (SWIS) 4 Infection remover (drug) Market access and sales strategy Infection prevention market size2 ▪ To secure market access Million acute wounds annually ▪ Clinical development plan Traumatic wounds ▪ Excite International 50.0 ▪ KOL – University of Copenhag
Slide 22: Existing products shall cover overheads and indirect costs
Existing products shall cover overheads and indirect costs 1 Hand hygiene - Antibac ▪ Distribution agreement with Kiiltoclean – the market leader in disinfection for healthcare industry ▪ Antibac-brand – strong brand recognition ▪ Premium non-alcoholic antimicrobial hand disinfection ▪ Provides acce
Slide 23: Intended use of proceeds – cash positive on operations
Intended use of proceeds – cash positive on operations 1 Enter the hand disinfectant market – NOK 10 mill 2 Enter the animal health market – NOK 8 mill 3 Increase production capacity – NOK 2 mill Infection remover – NOK 25 mill 4 ▪ Conduct phase 1 and phase 2 trials (PoC) on infection remover wounds
Slide 24: Key assumptions for market penetration – first two products
Key assumptions for market penetration – first two products* Targets 2020 2021 2022 2023 2024 2025 Hand disinfection No. of users 3,500 14,000 37,000 75,000 180,000 360,000 Target market share 0.5% 2% 1.3% 1.2% 2.1% 4.2% Markets N, S, DK, IS N, S, DK, IS N, S, DK, G N, S, DK, G, N, S, DK, G, EU UK,
Slide 25: Revenue target scenario
Revenue target scenario Revenue scenario based on following key assumptions Preliminary sales projections NOKm • First two years’ budget income are independent of costs 1,400 1,367 1,300 • Profit sharing with pilot partners assumed initially, later 60/40 1,200 1,100 • Price estimated to be 10% of ta
Slide 26: Investment proposition
Investment proposition $33B+ +80% Proven effect 2021 Large market Gross margin Successful clinical trial Ambition of cash opportunity1 target2 in humans positive operations Strong patent Leading distribution Collaboration with No antimicrobial family protecting IP partners world leading scientists r
Slide 27: Thank you for your attention!
Thank you for your attention!
Slide 28: Index and References
Index and References (DB) SOFT-OX
SoftOx Solutions AS — Investor Presentation (December 2019) on 6ix